Abstract 869
Background
Breast cancer contributes to 19-34% of all malignancies- indicating the high disease burden. In view of various socio-economic and cultural reasons, patients usually present at an advanced stage because of lack of awareness and nonexistent breast cancer screening programs in India. Breast self-examination (BSE) is easy cost effective and proven way for early detection.
Methods
Objective: 1. To train women for Breast self-examination in health camps 2. To determine the effectiveness of planned teaching program with respect to BSE Materials & methods: Trained workers and physician prepared a visual aid and short video in local language for breast self examination and spend average 8-12 minutes to educate a group of women. 15:1 random check was done to known their level of understanding and correctness of adopting the method. The participants were observed and supervised by doctors to complete the procedure successfully. The results of Breast Self-Examination were documented.
Results
BSE was successfully trained for a total of 4965 women across 19 camps between 2018-2019. Out of the samples 93% of women understood accurately the right method of BSE and re-traing was felt necessary in 35% as per their perception. Among the camps 165 new cases were reported in participants. Upon physician’s examination 132 suspected participants were referred for mammographic evaluation at medical centers and malignancies were detected in 76 participants, which indicates high impact of such training programs in rural India.
Conclusions
Conclusion: cancer awareness and education programs should be an integral part of health camps to improve women’s health and BSE Is easy to teach and have positive impact for early detection of cancer (the detection rate of 1.5% was quite high especially in the rural areas where medical facilities are poor). If implemented in structured manner BSE is the best and cheapest option for screening women of all ages in Indian population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3139 - Efficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy.
Presenter: Nieves Martinez Lago
Session: Poster Display session 2
Resources:
Abstract
3446 - Fluoropyrimidine-induced cardiotoxicity in colorectal cancer patients: preliminary data from the prospective observational CHECKPOINT trial (NCT02665312)
Presenter: Pasquale Lombardi
Session: Poster Display session 2
Resources:
Abstract
3969 - Comparable survival outcome between Thai patients with sporadic young adult and adult onset colorectal cancer
Presenter: Kanjana Sukhokanjanachusak
Session: Poster Display session 2
Resources:
Abstract
4455 - Impact of primary tumor side on 3-year survival outcomes of first-line (1L) FOLFOX-4 ± cetuximab in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial
Presenter: Shukui Qin
Session: Poster Display session 2
Resources:
Abstract
4481 - Undetectable RAS mutant clones in plasma: possible implication for therapy and prognosis in the patient with RAS mutant metastatic colorectal cancer?
Presenter: Mohamed Bouchahda
Session: Poster Display session 2
Resources:
Abstract
5074 - Dihydropyrimidine dehydrogenase (DPD) determination prior the administration of medicines containing fluorouracil: a single Spanish hospital experience.
Presenter: Maria Dolores Mediano Rambla
Session: Poster Display session 2
Resources:
Abstract
5242 - Differences in survival between right and left-sided colorrectal cancer (CRC) in every stage, a CARESS-CCR Group Study.
Presenter: Julia Alcaide-Garcia
Session: Poster Display session 2
Resources:
Abstract
1123 - Quality of Life (QoL) in patients with aflibercept (AFL) and FOLFIRI for metastatic colorectal cancer (mCRC) – Interim analysis with focus on mutational status of the non-interventional study QoLiTrap (AIO-LQ-0113)
Presenter: Roger von Moos
Session: Poster Display session 2
Resources:
Abstract
1212 - The cost of adverse event management in patients with RAS wild-type metastatic colorectal cancer treated with first-line cetuximab and panitumumab: an Italian healthcare payer perspective
Presenter: Karl Patterson
Session: Poster Display session 2
Resources:
Abstract
1619 - Meta-analysis of KRAS Mutation as prognostic factor in patients (pts.) with resection of colorectal (CRC) liver metastases: Tumor burden and Sideness analysis.
Presenter: Maria Romina Luca
Session: Poster Display session 2
Resources:
Abstract